CompanyCompetitive AnalysisCompany Patent Opposition Analysis

Explore patent oppositions filed by Crispr Therapeutics against competitors, revealing strategic technology disputes and market positioning. Monitor opposition details, timelines, and disputed innovations to understand competitive dynamics and IP enforcement strategy.

Last updated on: Aug 7, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

Rna-Guideded Transcriptional RegulationPRESIDENT AND FELLOWS OF HARVARD COLLEGEAug 11, 2022
Composition For Cleaving A Target Dna Comprising A Guide Rna Specific For The Target Dna And Cas Protein-Encoding Nucleic Acid Or Cas Protein, And Use ThereofTOOLGEN INCORPORATEDJun 2, 2022
Delivery, Engineering And Optimization Of Systems, Methods And Compositions For Sequence Manipulation And Therapeutic ApplicationsMASSACHUSETTS INSTITUTE OF TECHNOLOGYApr 7, 2021
Delivery And Use Of The Crispr-Cas Systems, Vectors And Compositions For Hepatic Targeting And TherapyMASSACHUSETTS INSTITUTE OF TECHNOLOGYNov 13, 2020
Crispr-Cas Component Systems, Methods And Compositions For Sequence ManipulationMASSACHUSETTS INSTITUTE OF TECHNOLOGYOct 29, 2020
Engineering Of Systems, Methods And Optimized Guide Compositions For Sequence ManipulationMASSACHUSETTS INSTITUTE OF TECHNOLOGYMar 19, 2020
Engineering And Optimization Of Improved Systems, Methods And Enzyme Compositions For Sequence ManipulationMASSACHUSETTS INSTITUTE OF TECHNOLOGYFeb 10, 2020
Inducible Dna Binding Proteins And Genome Perturbation Tools And Applications ThereofMASSACHUSETTS INSTITUTE OF TECHNOLOGYFeb 10, 2020
Engineering Of Systems, Methods And Optimized Guide Compositions For Sequence ManipulationMASSACHUSETTS INSTITUTE OF TECHNOLOGYNov 5, 2019
Methods, Models, Systems, And Apparatus For Identifying Target Sequences For Cas Enzymes Or Crispr-Cas Systems For Target Sequences And Conveying Results ThereofMASSACHUSETTS INSTITUTE OF TECHNOLOGYFeb 28, 2019

Top competitors of Crispr Therapeutics

List of top competitors of Crispr Therapeutics based on patent oppositions.